Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Azitra, Inc.

Azitra to Present at BIO-Europe 2024
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates
From Azitra, Inc.
Via Business Wire
Tickers AZTR
CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Pricing of $10.0 Million Public Offering
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Reverse Stock Split
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Closing of Public Offering
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Pricing of Public Offering
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra to Present at the ThinkEquity Conference
From Azitra, Inc.
Via Business Wire
Tickers AZTR
Azitra Appoints Francisco Salva as Chief Executive Officer
From Azitra, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.